Multiple therapeutic options are available for the management of patients with upper urinary tract transitional cell carcinoma (TCC). Radical nephroureterectomy with an ipsilateral bladder cuff is the ...
p53, p21, and pRb expression was examined immunohistochemically on archival radical cystectomy samples from 164 patients with invasive or high-grade recurrent superficial transitional cell carcinoma ...
PURPOSE: The aim of this phase I study was to determine the safety and toxicity profile of gemcitabine administered as an intravesical agent in patients with transitional-cell carcinoma (TCC) of the ...
Transitional cell carcinoma (TCC) is the most common form of urinary bladder cancer in dogs, presenting significant challenges in both diagnosis and management. This high‐grade invasive neoplasm ...
The FDA approval of nivolumab plus cisplatin and gemcitabine marks the first concurrent immunotherapy-chemotherapy combination for the population. The trial showed the combination significantly ...
A new combination of cancer medications appears to extend overall survival in patients with advanced bladder cancer more than the chemotherapies currently used as the standard of care. The research, ...
The American Cancer Society estimates that over 80,000 individuals will be diagnosed with bladder cancer this year.
Nat Clin Pract Urol. 2007;4(8):432-443. JD Raman is a Chief Resident in Urology and DS Scherr is an Assistant Professor of Urology at the New York Presbyterian Hospital–Weill Cornell Medical Center, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results